Related Experiment Video
Updated: Jun 11, 2026
Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
Published on: March 28, 2013
Effects of rosiglitazone on inflammation in Otsuka long-evans Tokushima Fatty rats
Jin Woo Lee1, Il Seong Nam-Goong, Jae Geun Kim
1Department of Internal Medicine, Ulsan University Hospital, Ulsan University Collage of Medicine, Ulsan, Korea.
Background:
Inflammation plays a role in the response to metabolic stress in type 2 diabetes. However, the effects of rosiglitazone on inflammation of skeletal muscle have not been fully examined in type 2 diabetes.
Methods:
We investigated the effects of the insulin-sensitizing anti-diabetic agent, rosiglitazone, on the progression of skeletal muscle inflammation in Otsuka Long-Evans Tokushima Fatty (OLETF) type 2 diabetic rats. We examined the expression of serologic markers (serum glucose, insulin and free fatty acid) and inflammatory cytokines (tumor-necrosis factor-alpha, interleukin [IL]-1beta and IL-6) in OLETF rats from early to advanced diabetic stage (from 28 to 40 weeks of age).
Results:
Serum glucose and insulin concentrations were significantly decreased in rosiglitazone-treated OLETF rats compared to untreated OLETF rats. Rosiglitazone treatment significantly decreased the concentrations of serum inflammatory cytokines from 28 to 40 weeks of age. The mRNA expression of various cytokines in skeletal muscle was reduced in rosiglitazone-treated OLETF rats compared with untreated OLETF rats. Furthermore, rosiglitazone treatment resulted in the downregulation of ERK1/2 phosphorylation and NF-kappaB expression in the skeletal muscle of OLETF rats.
Conclusion:
These results suggest that rosiglitazone may improve insulin sensitivity with its anti-inflammatory effects on skeletal muscle.
Insights
Rosiglitazone treatment reduced inflammation and improved insulin sensitivity in type 2 diabetic rats. This study shows rosiglitazone
Area of Science:
- Endocrinology
- Metabolic Diseases
- Molecular Biology
Background:
- Inflammation is implicated in metabolic stress in type 2 diabetes.
- Skeletal muscle inflammation's response to rosiglitazone is not fully understood in type 2 diabetes.
Purpose of the Study:
- To investigate rosiglitazone's effects on skeletal muscle inflammation in type 2 diabetic rats.
- To examine serologic markers and inflammatory cytokines in response to rosiglitazone treatment.
Main Methods:
- Utilized Otsuka Long-Evans Tokushima Fatty (OLETF) type 2 diabetic rats.
- Assessed serum glucose, insulin, free fatty acid, and inflammatory cytokines (TNF-α, IL-1β, IL-6).
- Examined mRNA expression of cytokines, ERK1/2 phosphorylation, and NF-κB in skeletal muscle.
Main Results:
- Rosiglitazone significantly decreased serum glucose, insulin, and inflammatory cytokine levels.
- Reduced mRNA expression of cytokines and downregulated ERK1/2 phosphorylation and NF-κB in skeletal muscle.
- Demonstrated anti-inflammatory effects in skeletal muscle of OLETF rats.
Conclusions:
- Rosiglitazone exhibits anti-inflammatory effects on skeletal muscle.
- These effects may contribute to improved insulin sensitivity in type 2 diabetes.
